Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Remodeling KRAS.

Structure (London, England : 1993) - 5 Sept 2017

Deredge Daniel J, Wintrode Patrick L

Abstract excerpt

Mutations in members of the RAS family of small GTPases have been associated with numerous human cancers. However, RAS family members are notoriously difficult to target. In this issue of Structure, Lu et al. (2017) examine the effects of two compounds with distinct chemical scaffolds on the structure and dynamics of an oncogenic KRAS mutant, thus highlighting the usefulness of HDX-MS for drug development.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Proto-Oncogene Proteins p21(ras)
Share to ras Proteins
Share to KRAS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydrogen

Share to Mass Spectrometry

Share to Mutation

Share to Deuterium

Source

Identifiers

PMID: 28877504
DOI: 10.1016/j.str.2017.08.012

Genes

KRAS
HDX

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Remodeling KRAS.PMID 28877504Read ↗

Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.Semantic proximity Read ↗

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways.Semantic proximity Read ↗

Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.Semantic proximity Read ↗

Stopping the beating heart of cancer: KRAS reviewed.Semantic proximity Read ↗

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRASSemantic proximity Read ↗

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.Semantic proximity Read ↗

Annual review of KRAS inhibitors in 2022.Semantic proximity Read ↗

Crystallographic Studies of KRAS in Complex with Small Molecules and RAS-Binding Proteins.Semantic proximity Read ↗

Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.Semantic proximity Read ↗

Progress in targeting RAS with small molecule drugsSemantic proximity Read ↗

Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.Semantic proximity Read ↗

Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.